Trending
Luigi Mangione pleaded guilty to federal stalking charges ahead of his New York murder trial over the killing of a UnitedHealthcare executive, set to begin next month.
Anthropic’s IPO valuation is built on a $190-200B revenue forecast for 2028, not current financials — a rare and aggressive Wall Street pricing move.
Lucid delayed its Cosmos SUV amid dwindling liquidity. The move looks like capital discipline, but raises questions about whether the company can execute its roadmap.
U.S. stocks hit a record after July inflation data showed improvement, while Asian shares fell mostly lower and U.S. futures stayed little changed.
Dell shares have roughly quadrupled in 2024, outpacing Micron and AMD. Lenovo’s latest earnings report pushed Dell’s gains further as demand signals align.
Birkenstock raised its full-year revenue forecast Wednesday, citing resilient full-price demand from affluent shoppers for its premium sandals.
Anthropic’s IPO valuation is built on a $190-200B revenue forecast for 2028, not current financials — a rare and aggressive Wall Street pricing move.
Birkenstock raised its full-year revenue forecast Wednesday, citing resilient full-price demand from affluent shoppers for its premium sandals.
Just In
Luigi Mangione pleaded guilty to federal stalking charges ahead of his New York murder trial over the killing of a UnitedHealthcare executive, set to begin next month.
Trump’s vaccine executive order is raising alarms among pediatricians as measles spreads, immunization rates fall, and children return to school.
Clothing retailers are offering repairs and sewing workshops to attract Gen Z shoppers motivated by both saving money and reducing environmental waste.
The U.S. Senate passed a resolution adding Missouri to the 1960 college football national title claimants, raising questions about legislative resources and athletic prestige economics.
Finance
Lucid delayed its Cosmos SUV amid dwindling liquidity. The move looks like capital discipline, but raises questions about whether the company can execute its roadmap.
Editor's Picks
Boston Scientific director Habiger bought $100K in BSX shares, expanding his stake 14% as the stock sits near a 54% decline and multi-year lows.
Latest
Retail insider Vecchio sold $620K in stock under a preplanned Rule 10b5-1 schedule while retaining 77,661 shares valued at $28.60 million.
